The genomic, transcriptomic, and immunologic landscape in solid tumors expressing leukocyte immunoglobulin like receptor B2
Sandra Jones, Harris Krause, Jose Noy, Samuel Kareff, Asaad Trabolsi, Andrew Elliott, Alex Farrell, Balazs Halmos, Patrick Ma, Wafik El-
Deiry, Ari Vanderwalde, Milan Radovich, George Sledge, Gilberto Lopes
The genomic landscape of high versus low LILRB2 expressors varied widely by cancer type.
LILRB2 expression was associated with biomarkers of response to immunotherapy such as PD-L1+ and an increased proportion of T cellinflamed tumors.
High expression of LILRB2 was associated with improved time on treatment with pembrolizumab in Methods NSCLC.
These data suggest that PDAC, NSCLC and UC tumors could potentially benefit from a combination of immune checkpoint inhibitors and LILRB2- blocking antibodies.